The University of Southampton
University of Southampton Institutional Repository

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
BACKGROUND AND OBJECTIVES: Recently, a chimeric monoclonal antibody (MoAb) directed against the CD20 antigen (rituximab) has been successfully introduced in the treatment of several CD20-positive B-cell neoplasias and particularly of follicular lymphomas. Based on these premises we evaluated the efficacy and the toxicity of chimeric anti-CD20 monoclonal antibody (MoAb) in relapsed/progressed hairy cell leukemia (HCL).

DESIGN AND METHODS: Ten patients with relapsed/progressed HCL entered the study. Eight patients were males and two females with a median age of 55 years (range 41-78) and all of them had been previously treated with 2-chlorodeoxyadenosine and/or deoxycoformycin and a-interferon. Two out of 10 patients were anemic (Hb < 10 g/dL), 4 thrombocytopenic (Plt < 100 x 10(9)/L), 3 had fewer than 1.0 x 10(9)/L neutrophils and 3 had circulating hairy cells (HC). All patients received 375 mg/m2 i.v. of anti-CD20 MoAb once a week for 4 doses.

RESULTS: All patients were evaluable for response, one patient showing a complete remission and 4 a partial response. Adverse reactions, such as fever, chills, bone pain, hypotension and thrombocytopenia, were transient and mild (grade 1-2) and occurred only during the first course of treatment. One month after the last infusion, patients who had had anemia, neutropenia or thrombocytopenia, recovered normal peripheral blood values. Circulating HC also disappeared within one month. Immunostained bone marrow biopsies were checked 1, 3 and 6 months after the end of therapy and in 5 out of 10 patients a >50% reduction of bone marrow HC infiltration was recorded.

INTERPRETATION AND CONCLUSIONS: On the basis of these preliminary results observed in 10 patients with progressed HCL, it appears that treatment with anti-CD20 MoAb is safe and effective in at least 50% of patients, particularly in those with a less evident bone marrow infiltration (50%) and in those previously splenectomized.
HCL, anti-CD20, rituximab, 2-CdA, DCF
0390-6078
1046-1050
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Lenoci, Mariapia
e7a3fdb7-9263-45b1-b627-9d85c349abca
Annino, Luciana
2f524de4-d0e3-4863-9476-b8846f7bf00b
Raspadori, Donatella
185f6866-6d10-4f86-9add-72938cea80b3
Marotta, Giuseppe
7cfa6aac-457c-4b9c-a279-5988a69706c9
Bocchia, Monica
55dbb34d-ab5d-4828-a4a4-a1fef1b41bb6
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Gentili, Sara
fecd81fe-5600-478f-a132-ca55e4579c8a
La Manda, Michela
4bdd700f-5c7a-4c46-92fe-9b451aeab923
Marconcini, Silvia
8005d8d3-417e-4662-8568-8bd4415301b4
Tozzi, Monica
0ae30a30-361d-41b2-82d9-aed35e57d625
Baldini, Luca
9fd9b515-b59b-4a22-b1d5-cd25b26266d0
Zinzani, Pier Luigi
c8a817bb-0f54-4bde-90b2-d3339ed8fff5
Foà, Robin
1e05d518-cb40-4f40-9e0e-e734caacb2e9
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Lenoci, Mariapia
e7a3fdb7-9263-45b1-b627-9d85c349abca
Annino, Luciana
2f524de4-d0e3-4863-9476-b8846f7bf00b
Raspadori, Donatella
185f6866-6d10-4f86-9add-72938cea80b3
Marotta, Giuseppe
7cfa6aac-457c-4b9c-a279-5988a69706c9
Bocchia, Monica
55dbb34d-ab5d-4828-a4a4-a1fef1b41bb6
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Gentili, Sara
fecd81fe-5600-478f-a132-ca55e4579c8a
La Manda, Michela
4bdd700f-5c7a-4c46-92fe-9b451aeab923
Marconcini, Silvia
8005d8d3-417e-4662-8568-8bd4415301b4
Tozzi, Monica
0ae30a30-361d-41b2-82d9-aed35e57d625
Baldini, Luca
9fd9b515-b59b-4a22-b1d5-cd25b26266d0
Zinzani, Pier Luigi
c8a817bb-0f54-4bde-90b2-d3339ed8fff5
Foà, Robin
1e05d518-cb40-4f40-9e0e-e734caacb2e9

Lauria, Francesco, Lenoci, Mariapia, Annino, Luciana, Raspadori, Donatella, Marotta, Giuseppe, Bocchia, Monica, Forconi, Francesco, Gentili, Sara, La Manda, Michela, Marconcini, Silvia, Tozzi, Monica, Baldini, Luca, Zinzani, Pier Luigi and Foà, Robin (2001) Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica, 86 (10), 1046-1050. (PMID:11602410)

Record type: Article

Abstract

BACKGROUND AND OBJECTIVES: Recently, a chimeric monoclonal antibody (MoAb) directed against the CD20 antigen (rituximab) has been successfully introduced in the treatment of several CD20-positive B-cell neoplasias and particularly of follicular lymphomas. Based on these premises we evaluated the efficacy and the toxicity of chimeric anti-CD20 monoclonal antibody (MoAb) in relapsed/progressed hairy cell leukemia (HCL).

DESIGN AND METHODS: Ten patients with relapsed/progressed HCL entered the study. Eight patients were males and two females with a median age of 55 years (range 41-78) and all of them had been previously treated with 2-chlorodeoxyadenosine and/or deoxycoformycin and a-interferon. Two out of 10 patients were anemic (Hb < 10 g/dL), 4 thrombocytopenic (Plt < 100 x 10(9)/L), 3 had fewer than 1.0 x 10(9)/L neutrophils and 3 had circulating hairy cells (HC). All patients received 375 mg/m2 i.v. of anti-CD20 MoAb once a week for 4 doses.

RESULTS: All patients were evaluable for response, one patient showing a complete remission and 4 a partial response. Adverse reactions, such as fever, chills, bone pain, hypotension and thrombocytopenia, were transient and mild (grade 1-2) and occurred only during the first course of treatment. One month after the last infusion, patients who had had anemia, neutropenia or thrombocytopenia, recovered normal peripheral blood values. Circulating HC also disappeared within one month. Immunostained bone marrow biopsies were checked 1, 3 and 6 months after the end of therapy and in 5 out of 10 patients a >50% reduction of bone marrow HC infiltration was recorded.

INTERPRETATION AND CONCLUSIONS: On the basis of these preliminary results observed in 10 patients with progressed HCL, it appears that treatment with anti-CD20 MoAb is safe and effective in at least 50% of patients, particularly in those with a less evident bone marrow infiltration (50%) and in those previously splenectomized.

Full text not available from this repository.

More information

Published date: 1 October 2001
Keywords: HCL, anti-CD20, rituximab, 2-CdA, DCF
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 358185
URI: https://eprints.soton.ac.uk/id/eprint/358185
ISSN: 0390-6078
PURE UUID: 29c9ef69-aa1c-4a0a-842f-fab75bfa4ce9

Catalogue record

Date deposited: 12 Nov 2013 11:39
Last modified: 16 Jul 2019 21:21

Export record

Contributors

Author: Francesco Lauria
Author: Mariapia Lenoci
Author: Luciana Annino
Author: Donatella Raspadori
Author: Giuseppe Marotta
Author: Monica Bocchia
Author: Sara Gentili
Author: Michela La Manda
Author: Silvia Marconcini
Author: Monica Tozzi
Author: Luca Baldini
Author: Pier Luigi Zinzani
Author: Robin Foà

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×